BioXcel Therapeutics, Inc. BTAI PHARMA
Company Overview
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. On August 27, 2026, BioXcel Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Why Investors Should Care
Generates a return on equity of 73.2%, reflecting efficient use of shareholder capital.
Revenue has grown at a 19.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $642.00K (-71.7% YoY); net profit $-69.90M.
- Trailing 12 Months Year-on-year growth — revenue +51.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.63% |
| 1 Year: | 51.70% |
Stock Price Performance
| 1 Year: | -98.68% |
| 6 Months: | -95.00% |
| 3 Months: | -93.30% |
| 1 Month: | -91.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)20.16 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 73.2%.
- Compounding revenue at 19.6% over 5 years.
CONS
- Trading 98.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 20 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BTAI BioXcel Therapeutics, Inc. PHARMA | 0.07 | -0.03 | $2.19M | 0.00% | - | 73.22% | 19.63% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.00K | 206.00K | 457.00K | 341.00K | 582.00K | 1.10M | 214.00K | - | 168.00K | 120.00K | 98.00K | 256.00K | 206.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.00K | 107.00K | 11.00K | 32.00K | 283.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 154.00K | 13.00K | 87.00K | 224.00K | -77.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.25M | 15.87M | 14.12M | 10.51M | 10.15M |
| Operating Income | -529.00K | -565.00K | -917.00K | -4.29M | -3.24M | -5.12M | -7.42M | -8.63M | -9.13M | -15.00M | -21.43M | -24.77M | -26.38M | -27.61M | -26.81M | -31.48M | -36.29M | -38.99M | -51.20M | -52.41M | -48.30M | -24.16M | -17.30M | -15.29M | - | -10.10M | -15.85M | -14.03M | -10.28M | -10.22M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.19M | -14.89M | -26.46M | -8.07M | -8.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.99M | 4.22M | 4.37M | 4.40M | 4.20M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.25M | -19.19M | -30.91M | -12.54M | -12.69M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -529.00K | -565.00K | -917.00K | -4.28M | -3.03M | -4.89M | -7.20M | -8.47M | -9.02M | -14.91M | -21.42M | -24.75M | -26.38M | -27.62M | -26.81M | -31.47M | -37.67M | -41.80M | -52.80M | -53.52M | -50.49M | -26.79M | -8.30M | -13.65M | - | -7.25M | -19.19M | -30.91M | -12.54M | -12.69M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -1.08 | -1.11 | -0.96 | -1.12 | -1.35 | -1.49 | -1.84 | -1.83 | -1.72 | -13.89 | -3.30 | -5.15 | -3.57 | -1.50 | -2.45 | -2.18 | - | -0.54 |
| R&D Expense | 321.00K | 324.00K | 619.00K | 2.94M | 1.78M | 3.82M | 5.67M | 6.51M | 7.12M | 12.37M | 17.91M | 16.32M | 14.74M | 13.51M | 11.93M | 18.56M | 17.91M | 22.06M | 27.80M | 26.97M | 19.62M | 11.40M | 8.03M | 5.10M | - | 4.55M | 10.26M | 8.74M | - | 2.96M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 375.00K | 1.38M | 2.27M | 642.00K |
| Operating Income | -4.54M | -19.96M | -33.60M | -82.30M | -106.94M | -159.65M | -171.78M | -67.25M | -50.46M |
| Net Income | -4.54M | -19.27M | -32.97M | -82.17M | -106.93M | -165.76M | -179.05M | -59.60M | -69.90M |
| Diluted EPS | - | - | - | -3.79 | -4.05 | -5.92 | -98.33 | -23.51 | -5.73 |
| R&D Expense | 2.69M | 14.56M | 25.80M | 57.99M | 52.71M | 91.24M | 84.33M | 30.43M | 30.25M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.35M | 43.55M | 36.39M | 219.94M | 239.44M | 205.85M | 73.70M | 38.34M | 44.92M |
| Total Equity | -314.00K | -982.00K | 38.89M | 26.89M | 206.70M | 221.67M | 76.78M | -56.51M | -93.10M | -95.46M |
| Cash & Equivalents | - | 887.00K | 42.56M | 32.43M | 213.12M | 232.97M | 193.72M | 65.22M | 29.85M | 28.41M |
| Long Term Debt | - | - | - | - | - | - | 93.05M | 100.60M | 102.51M | 84.66M |
| Total Liabilities | - | 2.34M | 4.66M | 9.50M | 13.24M | 17.77M | 129.08M | 130.21M | 131.44M | 140.38M |
| Current Liabilities | - | 2.34M | 4.66M | 8.47M | 11.84M | 16.67M | 32.90M | 27.27M | 22.23M | 53.93M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.20M | -13.51M | -27.10M | -66.35M | - | -135.34M | -155.01M | -72.03M | -57.62M |
| Investing Cash Flow | - | -340.00K | -870.00K | -316.00K | - | -139.00K | -20.00K | 0 | 0 |
| Financing Cash Flow | 3.08M | 55.53M | 17.83M | 247.36M | - | 96.24M | 26.52M | 36.66M | 56.52M |
| Capital Expenditure | - | -340.00K | -870.00K | -316.00K | -445.00K | -139.00K | -20.00K | - | - |
| Free Cash Flow | - | -13.85M | -27.97M | -66.67M | - | -135.48M | -155.03M | -72.03M | -57.62M |
| Net Change in Cash | - | - | - | - | - | -39.24M | -128.50M | -35.37M | -1.10M |
| Share Buybacks | - | - | - | 9.02M | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -42,572.0% | -12,448.0% | -2,967.6% | -7,860.0% |
| Net Margin % | - | - | - | - | - | -44,201.9% | -12,974.9% | -2,630.1% | -10,887.4% |
| ROE % | 462.2% | -49.6% | -122.6% | -39.8% | -48.2% | -215.9% | 316.9% | 64.0% | 73.2% |
| ROCE % | 462.0% | -51.3% | -120.3% | -39.5% | -48.0% | -92.3% | -369.9% | -417.5% | 560.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Millennium Management Llc | 6.76% | 2.11M | $156.28K |
| 2 | Oaktree Capital Management LP | 4.41% | 1.38M | $102.00K |
| 3 | Vanguard Capital Management LLC | 2.94% | 919.54K | $67.95K |
| 4 | Oaktree Fund Advisors, LLC | 0.78% | 245.59K | $18.15K |
| 5 | Geode Capital Management, LLC | 0.77% | 242.25K | $17.90K |
| 6 | Blackrock Inc. | 0.57% | 179.43K | $13.26K |
| 7 | UBS Group AG | 0.50% | 158.06K | $11.68K |
| 8 | Citadel Advisors Llc | 0.48% | 149.22K | $11.03K |
| 9 | Vanguard Fiduciary Trust Co | 0.44% | 136.94K | $10.12K |
| 10 | State Street Corporation | 0.29% | 92.12K | $6.81K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BTAI
$BTAI stock is down 39% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNRUUyb2x6eTByaXdobE1pZGF2QTNVZ3dYWlppcVZKWHV5VnJpTUt4RGoxblBELXFZSU50blItbFNEdnpRX05YdXBpUDhZTUJ0TUpBMnlYWk5xd3R4UkNSRmdvY1ZoSElpY1dCR09BWU0zOVIwS1NTRk93VEdsS1RGcVZhaTkyekhOQmhGVn…
Post-Market Losers: Notable After-Hours Decliners - ChartMill
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQOUxoUmp3cDZtemJDczMtU0o4TVBaRDVzUy1fWS1CR3ptTlhtR2hza0pvLVV6RVg3ZXdWTHoyODNhRWtQd0plNS1LMUlyTTJaZExfLXFpczRUWjhsQU5tR0RRZ1JuQXRlMnI1azByWG5DUzk1VTMxSnN6TFhSc3pmaFk1WDZsc1ZpYlliRE…
BioXcel agrees to $77M DIP as Nasdaq delists - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOTW1xcUFZZGZSYk1fQV9JRU5hNGNmWnNuQ1BDN1dlNXl4WTlZN3RhQ2xXcFJfLVRsekI0d2QxQTVKMENxRkNLR3ExMkVpMDJkelI3X3FoZ2hQMUxhVllFUzJ4QmlVeDh0OWRHenpLc2RSdU1qWnB4eGxnR0pURmJXQ196MkFPU1VFT3RUQm…
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOR3NyV09LQ3hXYVRKQktuZk1ydDA0RXVadDk4ZUVxWWJOZ0x2N1RUcG1HakZkRlhsNnVPMzRRMVNONWdheTNibkpsZ3lxa2tFbl95RHVKMXZJRUhWemdtTVdfZ3dnamFsaXFsZ2hkMUVPSEVQX18tQTNyTmpXOFRtTHdIOFVEekxMWGhibk…
BioXcel Shares Up 8% Amid 143 Million Shares Exchanged Prior to Delisting - TechStock²
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOX2hMaXBtbXdjZWt1OWRuQ0JlaHNZQ0xSZE5GekxMeUZUZzZUNW1FZGNlWjRtaHhTQTVWbVRfZng3SW9VQThnZXZNb1YwY2hjZGdJemFDN0F1STktZVY4RUx1UE1FU3V1Mk1SZlJqTDRlMk5TRkhleTNqZG1kQm5zRVhuRTNneWtNRk1ZRF…
BTAI - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1YUDdvdHVaM2YtWmE5b0VRTkVKRGJIM0Z6VVN1LWM0TFRZT3plYS0zb3owTmpndmJ5TWg0UWVGVkRReWQxZVE?oc=5" target="_blank">BTAI</a> <font color="#6f6f6f">Finviz</font>…
BTAI — Frequently Asked Questions
What is the current share price of BioXcel Therapeutics, Inc. (BTAI)?
As of 2026-09-19 21:16 PDT, BioXcel Therapeutics, Inc. (BTAI) trades at $0.07 on NasdaqCM. Its 52-week range is $0.07 to $5.67.
What is the market capitalisation of BTAI?
BioXcel Therapeutics, Inc. (BTAI) has a market capitalisation of $2.19M on NasdaqCM.
What is the P/E ratio of BTAI?
BTAI trades at a trailing price-to-earnings (P/E) ratio of -0.03. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.02.
What is the return on equity (ROE) of BTAI?
BTAI has a return on equity (ROE) of 73.22%.
Is BTAI a good stock to buy?
This page provides a data-driven analysis of BioXcel Therapeutics, Inc. (BTAI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.